2022年11月15日 · CD84 antigen is an immunoreceptor member of the SLAM family (SLAMF5), whose expression has been reported in certain immune cells and in B-cell malignancies. In this study, we show for the first time that CD84 is overexpressed in AML and present the first results of CD84-targeting CAR T-cells for the treatment of this disease.

2020年9月25日 · In vitro, platelet-derived soluble CD84 enhanced motility of wild-type but not of Cd84-/- CD4 + T cells suggesting homophilic CD84 interactions to drive this process. Clinically, human arterial blood directly sampled from the ischemic cerebral circulation indicated local shedding of platelet CD84.

CD84-mediated signaling regulates diverse immunological processes, including T cell cytokine secretion, natural killer cell cytotoxicity, monocyte activation, autophagy, cognate T:B interactions, and B cell tolerance at the germinal center checkpoint. Recently, alterations in CD84 have been related to autoimmune and lymphoproliferative disorders.

2022年11月15日 · With the goal of developing a novel and highly specific CAR-T cell approach for pediatric AML, we performed a large analysis of a gene expression dataset from AML patients and identified for the first time the CD84 as an AML specific antigen.

2021年2月22日 · CD84 is a self-binding immunoreceptor belonging to the signaling lymphocyte activation molecule (SLAM) family. Previously, we showed that CD84 bridges between chronic lymphocytic leukemia cells and their microenvironment, and it regulates T cell function. In the current study, we investigated the role of CD84 in MM.

2018年10月2日 · We showed that cell-cell interaction mediated through human and mouse CD84 upregulates PD-L1 expression on CLL cells and in their microenvironment and PD-1 expression on T cells. This resulted in suppression of T cell responses and activity in vitro and in vivo.

2019年7月1日 · CD84 (SLAMF5) is a cell surface receptor expressed on almost all leukocyte subsets. CD84 regulates cytotoxicity, cytokine secretion, autophagy, and T:B interactions. Polymorphisms in CD84 could serve as biomarkers to predict response to etanercept. CD84 mAb targeting reduces survival of chronic lymphocytic leukemia cells.

2024年11月26日 · Rabani et al. show that CD84 upregulation leads to increased immune suppression in the TME of TNBC. In Bregs, CD84 controls interleukin-10 expression through the β-catenin/Tcf4 pathway. Blocking CD84 potentiates anti-tumor immunity, thereby inhibiting tumor growth. Hence, the authors suggest CD84 as a therapeutic target for TNBC treatment.

Here, we show that platelet-derived sCD84 acts on CD4 + T-cell CD84 leading to enhanced CD4 + T-cell motility in vitro and aggravated infarct growth following cerebral I/R. Finally, we corroborated the clinical relevance of these findings by directly demonstrating reduced platelet CD84 levels in the ischemic circulation of stroke patients ...

2018年12月3日 · We showed that cell-cell interaction mediated through human and mouse CD84 upregulates PD-L1 expression on CLL cells and in their microenvironment and PD-1 expression on T cells. This resulted in suppression of T cell responses and activity in vitro and in vivo.